Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Santarus and Depomed have entered into a settlement agreement with Lupin and its subsidiary, Lupin Pharmaceuticals.
Subscribe to our email newsletter
The agreement resolved pending patent litigation involving GLUMETZA (extended release metformin tablets) 1000mg and 500mg.
According to the agreement, Lupin gains right to sell a generic version of GLUMETZA on 1 February 2016, or earlier under certain circumstances.
The settlement agreement is subject to review by the US Department of Justice and the Federal Trade Commission.
The agreement is also subject to entry by the US District Court for the Northern District of California of an order dismissing the litigation.